FDA Approves ATROPINE SULFATE — Edenbridge Pharmaceuticals LLC.

# FDA Approves Edenbridge Pharmaceuticals' Generic Atropine Sulfate Ophthalmic Formulation Edenbridge Pharmaceuticals LLC has received FDA approval for its generic atropine sulfate ophthalmic formulation (ANDA219013), entering a competitive market segment used for mydriasis and accommodation control in ophthalmology and potentially addressing pricing pressures in the ophthalmic therapeutic category. The approval expands Edenbridge's portfolio in the generic ophthalmic space and offers healthcare providers additional sourcing options for a widely-used eye care medication